Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with China’s Hansoh Pharmaceuticals Group Company to acquire exclusive clinical ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 million upfront for a preclinical GLP-1 drug the company hopes will have a ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals ... development and commercialization of a new obesity drug candidate outside of China. The deal, announced Monday, revolves around HS-20094, a GLP ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Regeneron also said it will license an experimental obesity drug from China's Hansoh Pharmaceuticals (3692.HK), opens new tab in a deal worth up to $2.01 billion. Weight-loss drugs from current ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals ... exclusive rights for the clinical development and commercialization of a new obesity drug candidate outside of China. The deal, announced Monday, ...